Status:
COMPLETED
Real-world Experience on the Use of Upadacitinib in the Treatment of Moderate-severe Adult Atopic Dermatitis (ERUDA)
Lead Sponsor:
Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18+ years
Brief Summary
Real-world experience on the use of Upadacitinib in the treatment of Adult moderate-severe atopic dermatitis
Detailed Description
Atopic dermatitis (DA) is a chronic-recurrent inflammatory skin disease with high prevalence in children. Clinical remission is frequently observed during or after childhood although it may persist an...
Eligibility Criteria
Inclusion
- Age 18 years
- Signature of informed consent
- Diagnosis of moderate and/or severe DA by a dermatologist specialist
- Approval of the compassionate use of upadacitinib
Exclusion
- Patient unable to give informed consent prior to any collection procedure study data
- unable to complete the procedures required for the study
Key Trial Info
Start Date :
December 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 19 2024
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT05989932
Start Date
December 15 2021
End Date
April 19 2024
Last Update
July 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Irccs Fondazione Policlinico Gemelli
Roma, ROMA, Italy, 00168